

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**(19) World Intellectual Property Organization
International Bureau**



A standard linear barcode is located at the bottom of the page, spanning most of the width. It is used for tracking and identification of the journal issue.

**(43) International Publication Date
4 January 2001 (04.01.2001)**

PCT

(10) International Publication Number
WO 01/00210 A1

(51) International Patent Classification⁷: A61K 31/4985, 31/519, C07D 487/04, 498/04, C07K 5/06, A61P 9/00, 29/00

Hwa-Ok [US/US]; 5606 154th Avenue Northeast, Redmond, WA 98052 (US). **STASIAK, Marcin** [PL/US]; #7306, 4331 Lake Washington Boulevard Northeast, Kirkland, WA 98033 (US).

(21) International Application Number: PCT/US00/17053

(74) Agents: HERMANN, Karl, R. et al.; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).

(22) International Filing Date: 20 June 2000 (20.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 09/244.221 25 June 1999 (25.06.1999) US

(71) *Applicant (for all designated States except US): MOLEC-UMETICS LTD. [US/US]; Suite 400, 2023 120th Avenue Northeast, Bellevue, WA 98005 (US)*


(72) Inventors; and
(75) Inventors/Applicants (*for US only*): KAHN, Michael [US/US]; 10916 80th Place Northeast, Kirkland, WA 98034 (US). EGUCHI, Masakatsu [JP/US]; 636 129th Place Northeast, Bellevue, WA 98005 (US). KIM,

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: REVERSE-TURN MIMETICS AND METHODS RELATING THERETO



WO 01/00210 A1

WO (57) **Abstract:** Conformationally constrained compounds which mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetics have utility in the treatment of cell adhesion-indicated diseases, such as multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease.



Published:

- *With international search report.*
- *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

REVERSE-TURN MIMETICS AND METHODS RELATING THERETO

Technical Field

5 The present invention relates generally to reverse-turn mimetics, including inhibitors of cell adhesion-mediated disease, as well as to a chemical library of reverse-turn mimetics.

Background of the Invention

10 Cell adhesion is critical to the viability of living organisms. Adhesion holds multicellular tissues together and directs embryonic development. It plays important roles in wound healing, eradication of infection and blood coagulation. Integrins are a family of cell surface proteins intimately involved in all of these functions. They have been found in nearly every type of human cell except red blood 15 cells. Abnormalities in integrin function contribute to a variety of disorders including inflammatory diseases, heart attack, stroke, and cancer.

Integrins consist of heterodimers of α and β subunits, non-covalently bound to each other. These cell surface receptors extend through the cell membrane into the cytoplasm. At least 15 different α and 9 different β subunits are known. 20 However, because most α proteins associate with only a single β there are about 21 known integrin receptors. On the cell surface the heads of the two subunits contact each other to form a binding surface for extracellular protein ligands, allowing attachment to other cells or to the extracellular matrix. The affinity of these receptors may be regulated by signals from outside or within the cell. For example, recruitment 25 of leukocytes to the site of injury or infection involves a series of adhesive interactions. Weak interaction between endothelial and leukocyte selectins and carbohydrates mediate transient adhesion and rolling of the leukocyte along the vessel wall. Various chemokines and other trigger factors released by the site of inflammation serve as signals to activate integrins from a quiescent to a high affinity state. These activated 30 integrins then bind their cognate ligands on the surface of the endothelial cells, resulting in strong adhesion and flattening of the leukocyte. Subsequently the leukocyte migrates through the endothelium into the tissue below.

Integrin $\alpha_4\beta_1$ mediates cell adhesion primarily through binding to either 35 vascular cell adhesion molecule-1 (VCAM-1) or an alternatively spliced variant of fibronectin containing the type III connecting segment (IIICS). A variety of cells involved in inflammation express $\alpha_4\beta_1$, including lymphocytes, monocytes, basophils

and eosinophils, but not neutrophils. Monoclonal antibodies to the α_4 subunit have been used to validate α_4 -containing integrins as potential therapeutic targets in animal models of rheumatoid arthritis (Barbadillo et al. *Springer Semin Immunopathol* 16: 427-36, 1995; Issekutz et al. *Immunology* 88: 569-76, 1996), acute colitis (Podolsky et al. *J Clin Invest* 92: 372-80, 1993), multiple sclerosis (Yednock et al. *Nature* 356: 63-6, 1992), asthma (Abraham et al. *J. Clin. Invest.* 93: 776-87, 1994; US 5,871,734) and diabetes (Tsukamoto et al. *Cell Immunol* 165: 193-201, 1995). More recently, low molecular weight peptidyl derivatives have been produced as competitive inhibitors of $\alpha_4\beta_1$ and one has been shown to inhibit allergic airway responses in sheep (Lin et al. *J Med Chem* 42: 920-34, 1999).

It has been shown that a key sequence in IIICS involved in binding to $\alpha_4\beta_1$ is the 25 residue peptide CS1, and within that sequence the minimally recognized motif is the tripeptide, LDV. A similar sequence, IDS, has been implicated in the binding of VCAM-1 to $\alpha_4\beta_1$. X-ray crystal structures of an N-terminal two-domain fragment of VCAM-1 show that the IDS sequence is part of an exposed loop linking two beta-strands (Jones et al. *Nature* 373: 539-44, 1995; Wang et al. *Proc Natl Acad Sci U S A* 92: 5714-8, 1995). Cyclic peptides and derivatives thereof which adopt reverse-turn conformations have proven to be inhibitors of VCAM-1 binding to $\alpha_4\beta_1$ (WO 96/00581; WO 96/06108; Doyle et al. *Int J Pept Protein Res* 47: 427-36, 1996). In addition, a number of potent and selective (versus $\alpha_5\beta_1$) cyclic peptide-based inhibitors have been discovered (Jackson et al. *J Med Chem* 40: 3359-68, 1997). Several non-peptidyl beta-turn mimetics have also been reported to bind $\alpha_4\beta_1$ with IC₅₀s in the low micromolar range (Souers et al. *Bioorg Med Chem Lett* 8: 2297-302, 1998). Numerous phenylalanine and tyrosine derivatives have also been disclosed as inhibitors of $\alpha_4\beta_1$ (WO 99/06390; WO 99/06431; WO 99/06433; WO 99/06434; WO 99/06435; WO 99/06436; WO 99/06437; WO 98/54207; WO 99/10312; WO 99/10313; WO 98/53814; WO 98/53817; WO 98/58902) However, no potent and orally available small molecule inhibitors have been disclosed.

A related integrin, $\alpha_4\beta_7$, is expressed on the surface of lymphocytes and binds VCAM-1, fibronectin and mucosal addressin cell adhesion molecule 1 (MAdCAM-1). Integrin $\alpha_4\beta_7$ and MAdCAM mediate recirculation of a subset of lymphocytes between the blood, gut, and lymphoid tissue. Similar to VCAM-1 and Fibronectin CS-1 there is a tripeptide sequence, LDT, present on the CD loop of MAdCAM-1 which is important for recognition by $\alpha_4\beta_7$. An X-ray crystal structure shows this sequence is also part of a turn structure (Tan et al. *Structure* 6: 793-801, 1998). Recent studies have shown that $\alpha_4\beta_7$ may also play a part in diseases such as

asthma (Lobb et al. *Ann N Y Acad Sci* 796: 113-23, 1996), inflammatory bowel disease (Fong et al. *Immunol Res* 16: 299-311, 1997), and diabetes (Yang et al. *Diabetes* 46: 1542-7, 1997). In addition, while α_4 integrins appear to be down-regulated in carcinomas such as cervical and prostate, they appear to be up-regulated in metastatic 5 melanoma (Sanders et al. *Cancer Invest* 16: 329-44, 1998), suggesting that inhibitors of $\alpha_4\beta_1$ and $\alpha_4\beta_7$ may be useful as anticancer agents.


Reverse-turns comprise one of three classes of protein secondary structure and display three (gamma-turn), four (beta-turns), or more (loops) amino acid side chains in a fixed spatial relationship to each other. Turns have proven important in 10 molecular recognition events (Rose et al. *Advances in Protein Chemistry* 37: 1-109, 1985) and have engendered a burgeoning field of research into small molecule mimetics of them (e.g. Hanessian et al. *Tetrahedron* 53: 12789-12854, 1997). Many mimetics have either been external turn-mimetics which do not allow for the display of all the physiologically relevant side-chains (e.g. Freidinger et al. *Science* 210: 656-8, 1980) or 15 small, conformationally mobile cyclic peptide derivatives (e.g. Viles et al. *Eur J Biochem* 242: 352-62, 1996). However, non-peptide compounds have been developed which closely mimic the secondary structure of reverse-turns found in biologically active proteins or peptides. For example, U.S. Patent No. 5,475,085, 5,670,155 and 5,672,681, to Kahn and published PCT WO94/03494 to Kahn all disclose 20 conformationally constrained, non-peptidic compounds which mimic the three-dimensional structure of reverse-turns. More recently, published PCT WO97/15577 to Kahn and PCT WO98/49168 to Kahn et al. have disclosed additional, highly constrained bicyclic heterocycles as reverse-turn mimetics. Nevertheless, as no one template can mimic every type of turn, there remains a need in the art for additional 25 reverse-turn templates and methods for their use.

While significant advances have been made in the synthesis and identification of conformationally constrained, reverse-turn mimetics, there is still a need in the art for small molecules that mimic the secondary structure of peptides. In addition, there is a need in the art for techniques for synthesizing libraries of such 30 mimetics and screening the library members against biological targets to identify bioactive library members. Further, there is a need in the art for small, orally available inhibitors of integrins, for use in treating inflammatory diseases and cardiovascular diseases, as well as some cancers. In particular there is a need for inhibitors of $\alpha_4\beta_1$ and $\alpha_4\beta_7$, for use in the treatment of rheumatoid arthritis, asthma, diabetes and 35 inflammatory bowel disease. The present invention fulfills these needs, and provides further related advantages.

Summary of the Invention

In brief, the present invention is directed to conformationally constrained compounds which mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins. This invention also discloses libraries containing such compounds, as well as the synthesis and screening thereof. Furthermore, the invention discloses the use of reverse-turn mimetics for the treatment of cell adhesion-mediated diseases.


The compounds of the present invention have the following general structure (I):



(I)

wherein Y is selected from $-\text{CH}(\text{R}_5)\text{A}-\text{N}(\text{R}_1)-$, $-\text{A}-\text{N}(\text{R}_1)\text{-CH}(\text{R}')-$, $-\text{A}-\text{N}(\text{R}_1)\text{-C}(=\text{O})-$, $-\text{A}-\text{C}(=\text{O})\text{-N}(\text{R}_1)-$, $-\text{A}-\text{CH}(\text{R}_1)\text{-O}-$, and $-\text{A}-\text{CH}(\text{R}_1)\text{-N}(\text{R}')-$; A is $-(\text{CH}\text{R}')_n-$; B is $-(\text{CH}\text{R}'')_m-$; n = 0, 1 or 2; m = 1, 2 or 3; and any two adjacent CH groups or adjacent NH and CH groups on the bicyclic ring may optionally form a double bond; and wherein R', R'', R1, R2, R3, R4 and R5 are as defined in the following detailed description.


In the embodiment wherein Y is $-\text{CH}(\text{R}_5)\text{A}-\text{N}(\text{R}_1)-$, the compounds of this invention have the following structure (I'):



(I')

wherein A and B are as defined above, and R1, R2, R3, R4 and R5 are as defined in the following detailed description.

In the embodiment wherein Y is -A-N(R₁)-CH(R')-, the compounds of this invention have the following structure (I''):




5

(I'')

wherein A and B are as defined above, and R', R₁, R₂, R₃ and R₄ are as defined in the following detailed description.


10 In the embodiment wherein Y is -A-N(R₁)-C(=O)-, the compounds of this invention have the following structure (I'''):



(I''')

15 wherein A and B are as defined above, and R₁, R₂, R₃ and R₄ are as defined in the following detailed description.

In the embodiment wherein Y is -A-C(=O)-N(R₁)-, the compounds of this invention have the following structure (I''''):




20

(I''''')

wherein A and B are as defined above, and R₁, R₂, R₃ and R₄ are as defined in the following detailed description.

In the embodiment wherein Y is -A-CH(R₁)-O-, the compounds of this invention have the following structure (I^{'''}):


5



wherein A and B are as defined above, and R₁, R₂, R₃ and R₄ are as defined in the
10 following detailed description.

In the embodiment wherein Y is -A-CH(R₁)-N(R')-, the compounds of this invention have the following structure (I^{''''}):

15



wherein A and B are as defined above, and R', R₁, R₂, R₃ and R₄ are as defined in the following detailed description.

The present invention is also directed to libraries containing compounds
20 of structure (I) above, as well as methods for synthesizing such libraries and methods for screening the same to identify biologically active compounds. Methods of use for treating cell-adhesion-mediated disease with the compounds of this invention are described. Compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier or diluent are also disclosed.

25 These and other aspects of this invention will be apparent upon reference to the attached figures and following detailed description. To this end, various

references are set forth herein which describe in more detail certain procedures, compounds and/or compositions, and are incorporated by reference in their entirety.

Brief Description of the Drawings

5 Figure 1 illustrates the percent inhibition of radioligand binding to δ and μ opiate receptors of a representative reverse-turn mimetic of this invention as a function of concentration.


Figures 2-9 illustrate representative reaction schemes for the synthesis of reverse-turn mimetics of this invention.

10

Detailed Description of the Invention

The present invention is directed to reverse-turn mimetics and chemical libraries containing reverse-turn mimetics. The reverse-turn mimetics of the present invention are useful as bioactive agents, including (but not limited to) use as diagnostic, 15 prophylactic and/or therapeutic agents. The reverse-turn mimetic libraries of this invention are useful in the identification of such bioactive agents. In the practice of the present invention, the libraries may contain from tens to hundreds to thousands (or greater) of individual reverse-turn mimetics (also referred to herein as "members").

In one aspect of the present invention, a reverse-turn mimetic is 20 disclosed having the following structure (I):



(I)

25 wherein Y is selected from $-\text{CH}(\text{R}_5)\text{-A-N}(\text{R}_1)\text{-}$, $-\text{A-N}(\text{R}_1)\text{-CH}(\text{R}')\text{-}$, $-\text{A-N}(\text{R}_1)\text{-C(=O)}\text{-}$, $-\text{A-C(=O)-N}(\text{R}_1)\text{-}$, $-\text{A-CH}(\text{R}_1)\text{-O-}$ and $-\text{A-CH}(\text{R}_1)\text{-N}(\text{R}')\text{-}$; A is $-(\text{CHR}')_n$; B is $-(\text{CHR}')_m$; n = 0, 1 or 2; m = 1, 2 or 3; and any two adjacent CH groups or adjacent NH and CH groups on the bicyclic ring may optionally form a double bond; and wherein R', R", R₁, R₂, R₃, R₄ and R₅ are as defined below.

30 In structures (I') through (I"") above a solid line designation for attachment of the various R groups to a carbon atom on the fused bicyclic ring indicates that these R groups may lie either above or below the plane of the page. If a reverse-

turn mimetic of this invention is intended to mimic a reverse-turn of naturally occurring amino acids (*i.e.*, "L-amino acids"), the R groups would generally lie below the plane of the page (*i.e.*, " — R") in Structure (I). However, if the reverse-turn mimetic of this invention is intended to mimic a reverse-turn containing one or more D-amino acids, 5 then the corresponding R group or groups would lie above the plane of the page (*i.e.*, " — R") in Structure (I).

In one embodiment, R₁ and R₄ are the same or different and represent the remainder of the compound, and R', R", R₂, R₃, and R₅ are the same or different and independently selected from an amino acid side chain moiety or derivative thereof.

10 With regard to R' and R", it should be understood that each occurrence of R' and R" is independently selected from amino acid side chain moieties or derivatives thereof. For example, when m=2, B is a -CHR"CHR"- moiety. In this instance, both occurrences of R" are independently selected, and may be the same or different. Thus, if the first occurrence of R" is hydrogen and the second methyl, B would have the structure -





15 CH₂CH(CH₃)-.

As used herein, the term "remainder of the compound" means any moiety, agent, compound, support, molecule, linker, amino acid, peptide or protein covalently attached to the reverse-turn mimetic at either the R₁ and/or R₄ positions. This term also includes amino acid side chain moieties and derivatives thereof.

20 As used herein, the term "amino acid side chain moiety" represents any amino acid side chain moiety present in naturally occurring proteins including (but not limited to) the naturally occurring amino acid side chain moieties identified in Table 1. Other naturally occurring amino acid side chain moieties of this invention include (but are not limited to) the side chain moieties of 3,5-dibromotyrosine, 3,5-diiodotyrosine, 25 hydroxylysine, γ -carboxyglutamate, phosphotyrosine and phosphoserine. In addition, glycosylated amino acid side chains may also be used in the practice of this invention, including (but not limited to) glycosylated threonine, serine and asparagine.

30 Table 1
Amino Acid Side Chain Moieties

<u>Amino Acid Side Chain Moiety</u>	<u>Amino Acid</u>
-H	Glycine
-CH ₃	Alanine
-CH(CH ₃) ₂	Valine
-CH ₂ CH(CH ₃) ₂	Leucine

-CH(CH ₃)CH ₂ CH ₃	Isoleucine
-(CH ₂) ₄ NH ₃ ⁺	Lysine
-(CH ₂) ₃ NHC(NH ₂)NH ₂ ⁺	Arginine
	Histidine
-CH ₂ COO ⁻	Aspartic acid
-CH ₂ CH ₂ COO ⁻	Glutamic acid
-CH ₂ CONH ₂	Asparagine
-CH ₂ CH ₂ CONH ₂	Glutamine
	Phenylalanine
	Tyrosine
	Tryptophan
-CH ₂ SH	Cysteine
-CH ₂ CH ₂ SCH ₃	Methionine
-CH ₂ OH	Serine
-CH(OH)CH ₃	Threonine
	Proline
	Hydroxyproline

In addition to naturally occurring amino acid side chain moieties, the amino acid side chain moieties of the present invention also include various derivatives thereof. As used herein, a "derivative" of an amino acid side chain moiety includes 5 modifications and/or variations to naturally occurring amino acid side chain moieties. For example, the amino acid side chain moieties of alanine, valine, leucine, isoleucine and phenylalanine may generally be classified as lower chain alkyl, aryl, or aralkyl moieties. Derivatives of amino acid side chain moieties include other straight chain or branched, cyclic or noncyclic, substituted or unsubstituted, saturated or unsaturated 10 lower chain alkyl, aryl or aralkyl moieties.

As used herein, "lower chain alkyl moieties" contain from 1-12 carbon atoms, "lower chain aryl moieties" contain from 6-12 carbon atoms and "lower chain aralkyl moieties" contain from 7-12 carbon atoms. Thus, in one embodiment, the


amino acid side chain derivative is selected from a C₁₋₁₂ alkyl, a C₆₋₁₂ aryl and a C₇₋₁₂ aralkyl, and in a more preferred embodiment, from a C₁₋₇ alkyl, a C₆₋₁₀ aryl and a C₇₋₁₁ aralkyl.

Amino side chain derivatives of this invention further include substituted derivatives of lower chain alkyl, aryl, and aralkyl moieties, wherein the substituent is selected from (but are not limited to) one or more of the following chemical moieties: -OH, -OR, -COOH, -COOR, -CONH₂, -NH₂, -NHR, -NRR, -SH, -SR, -SO₂R, -SO₂H, -SOR and halogen (including F, Cl, Br and I), wherein each occurrence of R is independently selected from straight chain or branched, cyclic or noncyclic, substituted or unsubstituted, saturated or unsaturated lower chain alkyl, aryl and aralkyl moieties. Moreover, cyclic lower chain alkyl, aryl and aralkyl moieties of this invention include naphthalene, as well as heterocyclic compounds such as thiophene, pyrrole, furan, imidazole, oxazole, thiazole, pyrazole, 3-pyrroline, pyrrolidine, pyridine, pyrimidine, purine, quinoline, isoquinoline and carbazole. Amino acid side chain derivatives further include heteroalkyl derivatives of the alkyl portion of the lower chain alkyl and aralkyl moieties, including (but not limited to) alkyl and aralkyl phosphonates and silanes.

Representative R₁ and R₄ moieties specifically include (but are not limited to) -OH, -OR, -COR, -COOR, -CONH₂, -CONR, -CONRR, -NH₂, -NHR, -NRR, -SO₂R and -COSR, wherein each occurrence of R is as defined above.

In a further embodiment, and in addition to being an amino acid side chain moiety or derivative thereof (or the remainder of the compound in the case of R₁ and R₄), R₁, R₂, R₃, R₄, or R₅ may be a linker facilitating the linkage of the compound to another moiety or compound. For example, the compounds of this invention may be linked to one or more known compounds, such as biotin, for use in diagnostic or screening assay. Furthermore, R₁, R₂, R₃, R₄ or R₅ may be a linker joining the compound to a solid support (such as a support used in solid phase peptide synthesis) or alternatively, may be the support itself. In this embodiment, linkage to another moiety or compound, or to a solid support, is preferable at the R₁ or R₄ position, and more preferably at the R₄ position.


In the embodiment where Y is -CH(R₅)-A-N(R₁)-, the reverse-turn mimetic has the following structure (I'):



(I')

wherein A, B, R₁, R₂, R₃, R₄ and R₅ are as defined above. In a preferred embodiment, R₁ and R₄ represent the remainder of the compound, and R₂, R₃ and R₅ are individually selected from an amino acid side chain moiety.

In a more specific embodiment of structure (I'), A is -(CH₂)_n-, B is -(CH₂)_m-, and the reverse-turn mimetic has the following structure (Ia'):




10

(Ia')

wherein n, m, R₁, R₂, R₃, R₄ and R₅ are as defined above. In a preferred embodiment, R₁ and R₄ represent the remainder of the compound, and R₂, R₃ and R₅ are individually selected from an amino acid side chain moiety.


In a yet more specific embodiment of structure (I'), A is -(CH₂)_n-, B is -(CH₂)_m-, n is 0, m is 1 and the reverse-turn mimetic has the following structure (Ib'):



(Ib')

wherein R₁, R₂, R₃, R₄ and R₅ are as defined above. In a preferred embodiment, R₁ and R₄ represent the remainder of the compound, and R₂, R₃ and R₅ are individually selected from an amino acid side chain moiety. In another preferred embodiment, R₁ is selected from ROC(O)-, RSO₂- and RNHC(O)-, wherein R is as defined above. In a 5 more preferred embodiment, R₁ is selected from ROC(O)-, RSO₂- and RNHC(O)- and R is selected from substituted or unsubstituted lower chain aryl and lower chain aralkyl moieties. In another specific embodiment, R₂ and R₅ are independently selected from lower chain alkyl moieties, substituted with COOH or COOR, wherein R is as defined above. In another specific embodiment, R₃ is selected from substituted or unsubstituted 10 lower chain aryl and lower chain aralkyl moieties.


In the embodiment where Y is -A-N(R₁)-CH(R')-, the reverse-turn mimetic has the following structure (I''):



(I'')

15 wherein A, B, R₁, R₂, R₃, R₄ and R' are as defined above. In a preferred embodiment, R₁ and R₄ represent the remainder of the compound, and R₂, R₃ and R' are individually selected from an amino acid side chain moiety.


In an embodiment of structure (I'') where two adjacent CH groups on the bicyclic ring form a double bond, the reverse-turn mimetics of this invention include the 20 following structure (Ia''):



(Ia'')

wherein A, B, R₁, R₂, R₃, R₄ and R' are as defined above. In a preferred embodiment, R₁ and R₄ represent the remainder of the compound, R₂ and R₃ are independently selected from an amino acid side chain moiety, and R' is hydrogen.


In a more specific embodiment of structure (Ia''), A is -(CH₂)_n-, B is -(CH₂)_m-, R' is hydrogen, and the reverse-turn mimetic has the following structure (Ib''):



(Ib'')

wherein n, m, R₁, R₂, R₃ and R₄ are as defined above.

10 In the embodiment where Y is -A-N(R₁)-C(=O)-, the reverse turn mimetic has the following structure (I''):




(I'')

15 wherein A, B, R₁, R₂, R₃ and R₄ are as defined above. In a preferred embodiment, R₁ and R₄ represent the remainder of the compound, and R₂ and R₃ are independently selected from an amino acid side chain moiety.

In a more specific embodiment of structure (I''), A is -(CH₂)_n-, B is -(CH₂)_m-, and the reverse-turn mimetic has the following structure (Ia''):

20




(Ia'')

wherein n, m, R₁, R₂, R₃ and R₄ are as defined above.

In the embodiment where Y is -A-C(=O)-N(R₁)-, the reverse turn mimetic has the following structure (I'''):


5



(I''')

wherein R₁, R₂, R₃ and R₄ are as defined above. In a preferred embodiment, R₁ and R₄ represent the remainder of the compound, and R₂ and R₃ are independently selected 10 from an amino acid side chain moiety.

In a more specific embodiment of structure (I'''), A is -(CH₂)_n-, B is -(CH₂)_m-, and the reverse-turn mimetic has the following structure (Ia'''):




15

(Ia''')

wherein n, m, R₁, R₂, R₃ and R₄ are as defined above.

In the embodiment where Y is -A-CH(R₁)-O-, the reverse-turn mimetic has the following structure (I''''):


20



(I''''')

wherein R₁, R₂, R₃ and R₄ are as defined above. In a preferred embodiment, R₁ and R₄ represent the remainder of the compound, and R₂ and R₃ are independently selected from an amino acid side chain moiety.


5 In a more specific embodiment of structure (I"""), A is -(CH₂)_n-, B is -(CH₂)_m-, and the reverse-turn mimetic has the following structure (Ia"""):



(Ia''''')

wherein n, m, R₁, R₂, R₃ and R₄ are as defined above.


10 In the embodiment where Y is -A-CH(R₁)-N(R')-, and adjacent NH and CH groups on the bicyclic ring form a double bond, the reverse-turn mimetics of this invention include the following structure (Ia'''''):



15 (Ia''''')

wherein A, B, R₁, R₂, R₃ and R₄ are as defined above. In a preferred embodiment, R₁ and R₄ represent the remainder of the compound, and R₂ and R₃ are independently selected from an amino acid side chain moiety.

20 In a more specific embodiment of structure (Ia'''''), A is -(CH₂)_n-, B is -(CH₂)_m-, and the reverse-turn mimetic has the following structure (Ib'''''):



(Ib'')

wherein n, m, R₁, R₂, R₃ and R₄ are as defined above.

In preferred embodiment of structure (I), R₁ is selected from ROC(O)-, RSO₂- AND RHNC(O)-, wherein R is as defined above. In a more specific embodiment, R₁ is selected from ROC(O)-, RSO₂- and RHNC(O) and R is selected from substituted or unsubstituted lower chain aryl and lower chain aralkyl moieties.


In a specific embodiment of structure (I), R₂ and R₅ are independently selected from lower chain alkyl moieties, substituted with COOH or COOR, wherein R is as defined above. In another specific embodiment of structure (I), R₂ and R₅ are independently selected from H- and RC(O)NH- wherein R is as defined above.

In another specific embodiment of structure (I), R₃ is selected from substituted or unsubstituted lower chain aryl and lower chain aralkyl moieties.

In another specific embodiment of structure (I), R₃ is selected from substituted or unsubstituted lower chain aryl and lower chain aralkyl, including heterocyclic, moieties.


The reverse-turn mimetics of the present invention may be prepared by utilizing appropriate starting component molecules (hereinafter referred to as "component pieces"). Briefly, in the synthesis of reverse turn mimetics having structure (I'), first and second component pieces are coupled to form a combined first-second intermediate, third and fourth component pieces are coupled to form a combined third-fourth intermediate (or, if commercially available, a single third intermediate may be used), the combined first-second intermediate and third-fourth intermediate (or third intermediate) are then coupled to provide a first-second-third-fourth intermediate (or first-second-third intermediate) which is cyclized to yield the reverse-turn mimetics of this invention. Alternatively, the reverse-turn mimetics of structure (I') may be prepared by sequential coupling of the individual component pieces either stepwise in solution or by solid phase synthesis as commonly practiced in solid phase peptide synthesis.

Within the context of the present invention, a "first component piece" has the following structure 1:

1

where R_4 and B are as defined above, and R is a protective group suitable for use in peptide synthesis. Suitable R groups include alkyl groups and, in a preferred embodiment, R is a methyl group. Such first component pieces may be readily synthesized by reductive amination by mating $\text{CH}(\text{OR})_2-(\text{CH}_2)_m\text{-CHO}$ with $\text{H}_2\text{N}-\text{R}_4$, or by displacement from $\text{CH}(\text{OR})_2-(\text{CH}_2)_m\text{-Br}$. Alternatively, one of the R -groups may be a linker and resin. Polystyrene resins, such as those typically used in peptide synthesis and containing the Wang linker (4-hydroxymethylphenoxybutyrate), are suitable.

10 A "second component piece" of this invention has the following structure 2:


2

15 where R_3 is as defined above, P is an amino protective group suitable for use in peptide synthesis, and X represents the leaving group of the activated carboxylic acid group. Preferred protective groups include t-butyl dimethylsilyl (TBDMS), BOC, Fmoc, and Alloc (allyloxycarbonyl). N-Protected amino acids are commercially available. For example, Fmoc amino acids are available from a variety of sources. The conversion 20 of these compounds to the second component pieces of this invention may be readily achieved by activation of the carboxylic acid group of the N-protected amino acid. Suitable activated carboxylic acid groups include acid halides where X is a halide such as chloride or bromide, acid anhydrides where X is an acyl group such as acetyl, reactive esters such as an N-hydroxybenzotriazole esters, N-hydroxysuccinimide esters 25 and pentafluorophenyl esters, and other activated intermediates such as the active

intermediate formed in a coupling reaction using a carbodiimide such as dicyclohexylcarbodiimide (DCC) or diisopropylcarbodiimide (DIC).

In the case of the azido derivative of an amino acid serving as the second component piece, such compounds may be prepared from the corresponding amino acid 5 by the reaction disclosed by Zaloom et al. (*J. Org. Chem.* **46**:5173-76, 1981).

A "third component piece" of this invention has the following structure 3:



3


10

where R₂ and R₅ are as defined above, and P is a carboxylic acid protective group such as a methyl or t-butyl group.

A "fourth component piece" of this invention has the following structure

4:

15




4

20 where R₁ is as defined above. Suitable fourth component pieces are commercially available from a variety of sources. Alternatively, the fourth component pieces may be readily prepared by standard organic synthetic techniques commonly utilized for the synthesis of primary amines.



25 More specifically, the reverse-turn mimetics of this invention of structure (I') are synthesized by reacting a first component piece with a second component piece to yield a combined first-second intermediate, followed by either reacting the combined first-second intermediate with third and fourth component pieces sequentially, or reacting the intermediate with a combined third-fourth intermediate to provide a combined first-second-third-fourth intermediate, and then cyclizing this 30 intermediate to yield the reverse-turn mimetic.

The general synthesis of a reverse-turn mimetic having structure I' may be synthesized by the following technique. A first component piece 1 is coupled to a second component piece 2 to yield, after N-deprotection, a combined first-second intermediate 1-2 as illustrated below:


5



The synthesis of the reverse-turn mimetic may be convergent, in which case a combined third-fourth intermediate 3-4 is prepared from the coupling of a third component piece 3 with a fourth component piece 4 to yield, after O-deprotection, a 10 combined third-fourth intermediate 3-4 as illustrated below:




In the case where n of structure (I) above is 1 or 2, an intermediate of the following structure 3-4' can be made as follows:






5

wherein A is $-(\text{CHR}')_n-$. Intermediate 3-4' may then be employed in place of intermediate 3-4 in the following reactions to yield a reverse-turn mimetic of this invention having structure (I'). Alternatively, in the case where n of structure (I) above 10 is 1, 2 or 3, 3-4' may be made from a beta-, gamma- or delta-amino acid derivative which is acylated or sulfonylated and then O-deprotected as follows:



Coupling of the combined intermediates 1-2 and 3-4 provides
 5 intermediate 1-2-3-4 which, upon cyclization, yield the reverse-turn mimetic (I') as
 illustrated below:

3 - 41 - 21 - 2 - 3 - 4(I') where $n=0$

The syntheses of representative component pieces of this invention are described in Example 1. The syntheses of representative combined first-second and 5 third-fourth intermediates are described in Examples 2 and 3, respectively. The coupling of these intermediates to form a representative combined first-second-third-fourth intermediate is described in Example 4. The cyclization of this intermediate to form a representative reverse-turn mimetic is described in Example 5.

In a preferred embodiment, the reverse-turn mimetic of structure (Ia') may be made in solution according to the reaction scheme set forth in Figure 2. In another preferred embodiment, the reverse-turn mimetic of structure (Ia') may be made on solid-phase according to the reaction scheme set forth in Figure 8 and described in

5 Example 8. In a more preferred embodiment, the reverse-turn mimetic of structure (Ia') may be made on solid-phase according to the reaction scheme set forth in Figure 9 and described in Example 10.

The reverse-turn mimetics of structures (I'') through (I''') may be made by techniques analogous to the modular component synthesis disclosed above, but with

10 10 appropriate modifications to the component pieces. More specifically, the reverse-turn mimetics of structures (I'') through (I''') may be made by the reaction schemes set forth in Figures 3-7. In particular, the reverse-turn mimetics of structures (Ib''), (Ia'''), (Ia'''), (Ia''') and (Ib''') may be made by the representative reaction schemes set forth in Figures 3, 4, 5, 6 and 7, respectively.

15 15 In another aspect of this invention, libraries containing reverse-turn mimetics of the present invention are disclosed. Once assembled, the libraries of the present invention may be screened to identify individual members having bioactivity. Such screening of the libraries for bioactive members may involve, for example, evaluating the binding activity of the members of the library or evaluating the effect the

20 20 library members have on a functional assay. Screening is normally accomplished by contacting the library members (or a subset of library members) with a target of interest, such as, for example, an antibody, enzyme, receptor or cell line. Library members which are capable of interacting with the target of interest are referred to herein as "bioactive library members" or "bioactive mimetics". For example, a

25 25 bioactive mimetic may be a library member which is capable of binding to an antibody or receptor, which is capable of inhibiting an enzyme, or which is capable of eliciting or antagonizing a functional response associated, for example, with a cell line. In other words, the screening of the libraries of the present invention determines which library members are capable of interacting with one or more biological targets of interest.

30 30 Furthermore, when interaction does occur, the bioactive mimetic (or mimetics) may then be identified from the library members. The identification of a single (or limited number) of bioactive mimetic(s) from the library yields reverse-turn mimetics which are themselves biologically active, and thus useful as diagnostic, prophylactic or therapeutic agents, and may further be used to significantly advance identification of

35 35 lead compounds in these fields.

Synthesis of the peptide mimetics of the library of the present invention may be accomplished using known peptide synthesis techniques, in combination with the first, second and third component pieces of this invention.) More specifically, any amino acid sequence may be added as any of the R₁, R₂, R₃, R₄ or R₅ moieties of the 5 conformationally constrained reverse-turn mimetic. Preferably the amino acid sequence may be added as the R₁ or R₄ moieties. To this end, the mimetics may be synthesized on a solid support (such as polystyrene utilizing 4-hydroxymethylphenoxybutyrate as a linker) by known techniques (see, e.g., John M. Stewart and Janis D. Young, *Solid Phase Peptide Synthesis*, 1984, Pierce Chemical Comp., Rockford, Illinois; Atherton, 10 E., Shepard, R.C. *Solid Phase Peptide Synthesis: A Practical Approach*; IRL: Oxford, 1989) or on a silyl-linked resin by alcohol attachment (see Randolph et al., *J. Am Chem. Soc.* 117:5712-14, 1995).

In addition, a combination of both solution and solid phase synthesis techniques may be utilized to synthesize the peptide mimetics of this invention. For 15 example, a solid support may be utilized to synthesize the linear peptide sequence up to the point that the conformationally constrained reverse-turn is added to the sequence. A suitable conformationally constrained reverse-turn mimetic which has been previously synthesized by solution synthesis techniques may then be added as the next "amino acid" to the solid phase synthesis (i.e., the conformationally constrained reverse-turn 20 mimetic, which has at least two reactive sites, may be utilized as the next residue to be added to the linear peptide). Upon incorporation of the conformationally constrained reverse-turn mimetic into the sequence, additional amino acids may then be added to complete the peptide bound to the solid support. Alternatively, the linear N-terminus and C-terminus protected peptide sequences may be synthesized on a solid support, 25 removed from the support, and then coupled to the conformationally constrained reverse-turn mimetic in solution using known solution coupling techniques.

In another aspect of this invention, methods for constructing the libraries are disclosed. Traditional combinatorial chemistry and parallel synthesis techniques (see, e.g., *The Combinatorial Index* Bunin, Academic Press, New York, 1998; Gallop 30 et al., *J. Med. Chem.* 37:1233-1251, 1994) permit a vast number of compounds to be rapidly prepared by the sequential combination of reagents to a basic molecular scaffold. For example, the above disclosed synthesis may be carried out using the directed sorting technique of Nicolaou and coworkers (Nicolaou, Xiao et al. *Angew. Chem. Int. Ed.* 34: 2289-2291, 1995). Presently, equipment for this technique is 35 commercially available from IRORI (La Jolla, CA). Alternatively, the above disclosed synthesis may be carried out by parallel synthesis using a 48- or 96-well plate format

wherein each well contains a fritted outlet for draining solvents and reagents (*A Practical Guide to Combinatorial Chemistry* Czarnik and DeWitt, Eds., American Chemical Society, Washington, D.C., 1997). Robbins (Sunnyvale, CA), Charybdis (Carlsbad, CA) and Bohdan (Chicago, IL) presently offer suitable equipment for this
5 technique.

In a further aspect of this invention, methods for screening the libraries for bioactivity and isolating bioactive library members are disclosed. The libraries of the present invention may be screened for bioactivity by a variety of techniques and methods. Generally, the screening assay may be performed by (1) contacting a library
10 with a biological target of interest, such as a receptor, and allowing binding to occur between the mimetics of the library and the target, and (2) detecting the binding event by an appropriate assay, such as by the colorimetric assay disclosed by Lam et al. (*Nature* 354:82-84, 1991) or Griminski et al. (*Biotechnology* 12:1008-1011, 1994). In a preferred embodiment, the library members are in solution and the target is
15 immobilized on a solid phase. Alternatively, the library may be immobilized on a solid phase and may be probed by contacting it with the target in solution.

As mentioned above, the reverse-turn mimetics of the present invention are useful as bioactive agents, such as diagnostic, prophylactic, and therapeutic agents. The opiate receptor binding activity of representative reverse-turn mimetics is presented
20 in Example 9. In this example, the reverse-turn mimetics of this invention were found to effectively inhibit the binding of a radiolabeled enkephalin derivative to the δ and μ opiate receptors. The data demonstrates the utility of these reverse-turn mimetics as receptor antagonists and as potential analgesic agents. In a further embodiment, the integrin binding activity of representative reverse-turn mimetics is presented in
25 Example 11. In this example, the reverse-turn mimetics were found to effectively displace CS1 peptide from Ramos cells. The data thus indicate the ability of reverse turn mimetics to antagonize $\alpha_4\beta_1$ integrins and serve as potential anti-inflammatory agents.

In another aspect, the present invention encompasses pharmaceutical
30 compositions prepared for storage or administration which comprise a therapeutically effective amount of a compound of the present invention in a pharmaceutically acceptable carrier or diluent. Therapy with inhibitors of cell adhesion is indicated for the treatment and prevention of a variety of inflammatory conditions, particularly rheumatoid arthritis, inflammatory bowel disease and asthma. Those experienced in
35 this field are readily aware of the circumstances requiring anti-inflammatory therapy. In addition, therapy with inhibitors of cell adhesion are indicated for any condition in

which an excess of integrin-mediated cell adhesion is a contributing factor, such as, for example, atherosclerosis.

The "therapeutically effective amount" of a compound of the present invention will depend on the route of administration, the type of warm-blooded animal being treated, and the physical characteristics of the specific animal under consideration. These factors and their relationship to determining this amount are well known to skilled practitioners in the medical arts. This amount and the method of administration can be tailored to achieve optimal efficacy but will depend on such factors as weight, diet, concurrent medication and other factors which as noted those skilled in the medical arts will recognize.

The "therapeutically effective amount" of the compound of the present invention can range broadly depending upon the desired affects and the therapeutic indication. Typically, dosages will be between about 0.01 mg/kg and 100 mg/kg body weight, preferably between about 0.01 and 10 mg/kg, body weight.

"Pharmaceutically acceptable carriers" for therapeutic use, including diluents, are well known in the pharmaceutical art, and are described, for example, in *Remingtons Pharmaceutical Sciences*, Mack Publishing Co. (Gennaro Ed. 1985). For example, sterile saline and phosphate-buffered saline at physiological pH may be used. Preservatives, stabilizers, dyes and even flavoring agents may be provided in the pharmaceutical composition. For example, sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid may be added as preservatives. In addition, antioxidants and suspending agents may be used.

Compounds of the present invention are useful for prevention and treatment of any condition in which an excess of integrin-mediated cell adhesion is a contributing factor. In particular, the compounds of the present invention are useful as agents for the prevention and treatment of inflammation and related conditions. In the practice of the methods of this invention, a composition containing a therapeutically effective amount of a compound of this invention is administered to a warm-blooded animal in need thereof. For example, the compounds of this invention may be administered to a warm-blooded animal that has been diagnosed with, or is at risk of developing a condition selected from rheumatoid arthritis, atherosclerosis, Alzheimer's disease, AIDS dementia, ARDS, asthma, allergies, inflammatory bowel disease, CNS inflammation, atopic dermatitis, type I diabetes, encephalitis, myocardial ischemia, multiple sclerosis, meningitis, nephritis, restenosis, retinitis, psoriasis, stroke and tumor metastasis.

Multiple sclerosis (MS) is a progressively debilitating autoimmune disease of the central nervous system. Presently the exact antigen triggering the immune response is unknown. However, macrophages appear to attack and initiate the destruction of the fatty myelin sheaths surrounding nerve fibers in the brain. In an 5 animal model of MS (experimental allergic encephalomyelitis) murine monoclonal antibodies to $\alpha_4\beta_1$ blocked adhesion of the leukocytes to the endothelium, and prevented inflammation of the central nervous system and subsequent paralysis of the animals (Yednock, Cannon et al. *Nature* 356: 63-6, 1992).

The compounds of the present invention may be used singularly, as a 10 combination of two or more compounds, or in combination with other known inhibitors of inflammation. For example the compounds of this invention may be used therapeutically with corticosteroids, non-steroidal anti-inflammatory agents, COX-2 inhibitors, matrix metalloprotease inhibitors or lipoxygenase inhibitors. The compounds of the invention can be administered in such oral forms as tablets, capsules (each of 15 which includes sustained release or timed release formulations), pills, powders, granules, elixers, tinctures, suspensions, syrups, and emulsions. Likewise, they may be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, intranasal, intrarectal or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts. The compounds may be administered 20 intraocularly or topically as well as orally or parenterally.

The compounds of this invention may be administered by inhalation, and thus may be delivered in the form of an aerosol spray from pressurized packs or nebulizers. The compounds may also be delivered as powders which may be formulated and the powder composition may be inhaled with the aid of an insufflation 25 powder inhaler device. A preferred delivery system for inhalation is the metered dose inhalation aerosol, which may be formulated as a suspension or solution of a compound of the invention in suitable propellants, such as fluorocarbons or hydrocarbons. Another preferred delivery system is the dry powder inhalation aerosol, which may be formulated as a dry powder of a compound of this invention with or without additional 30 excipients.

The compounds of the invention can be administered in the form of a depot injection or implant preparation which may be formulated in such a manner as to permit a sustained release of the active ingredient. The active ingredient can be compressed into pellets or small cylinders and implanted subcutaneously or 35 intramuscularly as depot injections or implants. Implants may employ inert materials

such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers manufactured by the Dow-Corning Corporation.

The compounds of the invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

The compounds of this invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The integrin inhibitors may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinlypyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartarnide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the integrin inhibitors may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.

The dose and method of administration can be tailored to achieve optimal efficacy but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize. When administration is to be parenteral, such as intravenous on a daily basis, injectable pharmaceutical compositions can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.

Tablets suitable for oral administration of active compounds of the invention can be prepared as follows:

	<u>Amount-mg</u>		
Active Compound	25.0	50.0	100.0
Microcrystalline cellulose	37.25	100.0	200.0
Modified food corn starch	37.25	4.25	8.5
Magnesium stearate	0.50	0.75	1.5

All of the active compound, cellulose, and a portion of the corn starch are mixed and granulated to 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 25.0, 50.0, and 5 100.0 mg, respectively, of active ingredient per tablet.

An intravenous dosage form of the above-indicated active compounds may be prepared as follows:

Active Compound	0.5-10.0mg
Sodium Citrate	5-50mg
Citric Acid	1-15mg
Sodium Chloride	1-8mg
Water for Injection (USP)	q.s. to 1 mL

10 Utilizing the above quantities, the active compound is dissolved at room temperature in a previously prepared solution of sodium chloride, citric acid, and sodium citrate in Water for Injection (USP, see page 1636 of United States Pharmacopoeia/National Formulary for 1995, published by United States Pharmacopoeia Convention, Inc., Rockville, Maryland, copyright 1994).

15 The following examples are provided for purposes of illustration, not limitation.


EXAMPLES

20 Example 1
Synthesis of Component Pieces

In this example, the synthesis of representative component pieces which may be combined to form the reverse-turn mimetics of the present invention is 25 disclosed.

A. Representative First Component Pieces

A first component piece having the following structure 1 was utilized:





1

where R_4 is as defined above, and R represents a protective group suitable for use in peptide synthesis. Suitable R groups include alkyl groups and, in a preferred embodiment, R is a methyl group.

Generally, the first component piece is prepared by N-alkylation of an amine with a dialkylacetal of a 2-haloethanal. The synthesis of a representative first component piece from phenethylamine and the dimethylacetal of 2-bromoethanal is depicted schematically below.

10




1a

In the procedure, 24 ml (3.43 ml, 20.3 mmol) of bromide and 2.8 ml (2.71 g. 22.3 mmol) phenethylamine was added 40 ml freshly distilled THF in a 150 ml argon charged round-bottom flask equipped with a reflux condenser. The reaction was heated at a gentle reflux for 24 hours, then volatiles were removed under reduced pressure and the residue was dissolved in 200 ml dichloromethane. The organic layer was washed with 2 x 100 ml sat. aq. sodium bicarbonate, sat. aq. sodium chloride, and dried over anhydrous sodium sulfate. Volatiles were removed under reduced pressure

and the residue dried for 3 hrs. under high vacuum to yield 3.5 g (83%) first component piece 1a (m=1) as a light brown oil used without further purification.

B. Representative Second Component Pieces

5 A representative second component piece of this invention is a reactive N-protected amino acid having an activated carboxylic acid group, or an azido derivative of an amino acid, as represented by the following structure 2:




2


10 where R₃ is as defined above, P is an amino protective group suitable for use in peptide synthesis, and X represents the leaving group of the activated carboxylic acid group. Preferred protective groups include t-butyl dimethylsilyl (TBDMS), BOC, Fmoc, and Alloc (allyloxycarbonyl). N-Protected amino acids are commercially available. For example, Fmoc amino acids are available from a variety of sources. The conversion
 15 of these compounds to the second component pieces of this invention may be readily achieved by activation of the carboxylic acid group of the N-protected amino acid. Suitable activated carboxylic acid groups include acid halides where X is a halide such as chloride or bromide, acid anhydrides where X is an acyl group such as acetyl, reactive esters such as an N-hydroxysuccinimide esters and p-nitrophenyl esters, and
 20 other activated intermediates such as the active intermediate formed in a coupling reaction using a carbodiimide such as dicyclohexylcarbodiimide (DCC). Similarly, the corresponding azido derivative may be prepared by known techniques. In a preferred embodiment, X is hydroxyl for HATU (0-(7-azabenzotriol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) coupling, or is fluorine for silicon mediated
 25 coupling.

C. Representative Third Component Pieces

A representative third component piece of this invention is an α,β -unsaturated carboxylic acid or derivative thereof having the following structure 3:

3

5 where R_2 and R_5 are as defined above, and P is a carboxylic acid protective group such as a methyl or *t*-butyl group. Such third component pieces may be obtained commercially, or synthesized from the commercially available aldehyde and the appropriate phosphorus ylide according to the following reaction scheme:



(see, Wadsworth and Emmons, *Org. Syn.* **45**:44, 1965).

10

D. Representative Fourth Component Pieces

A representative fourth component piece of this invention is a primary amine having the following structure **4**:

15

R_1-NH_2

4

where R_1 is as defined above. Suitable fourth component pieces are commercially available from a variety of sources. Alternatively, the fourth component pieces may be readily prepared by standard organic synthetic techniques commonly utilized for the synthesis of primary amines.


5

Example 2

Combined First-Second Intermediates: The Coupling of First and Second Component Pieces

10 The coupling of the component pieces to produce the reverse-turn mimetics of the present invention generally involve the formation of amide bonds. The amide bonds which link the pieces may be formed by standard synthetic peptide techniques and may be performed by either liquid or solid phase synthesis.

15 The coupling of the first and second component pieces provides, after deprotection, a combined first-second intermediate having the following structure 1-2:




1-2

where R , R_3 , and R_4 are as described above (in this example, R'' of structure (I') is/are hydrogen).

20 The preparation of a combined first-second intermediate is accomplished by amide bond formation between the amine of a first component piece 1 and the activated carboxylic acid group of a second component piece 2 followed by N-deprotection. The synthesis of a representative combined first-second intermediate is depicted schematically below.

25




In the procedure, to 650 mg (3.17 mmol) first component piece 1a prepared as
 5 described in Example 1A and 1 g (3.17 mmol) FMOC-glycine chloride, 2a, 10 ml
 freshly distilled benzene in a 25 ml argon charged round bottom flask was added 937
 mg (7 mmol) silver cyanide (AgCN), and the resulting reaction mixture was stirred
 vigorously for 48 hrs. The reaction was diluted to 25 ml w/ethyl acetate and filtered
 through a Celite plug. Volatiles were removed under reduced pressure and the residue
 10 was chromatographed using 20:80 ethyl acetate:hexane as the mobile phase over flash
 grade silica gel to yield 1.1 g (71%) of an amorphous solid.

To 400 mg (0.82 mmol) of the amorphous solid in 5 ml acetonitrile was added 1
 ml diethylamine (DEA) dropwise and the resulting reaction mixture was stirred at room
 temperature for 2 hrs. The volatiles were removed under reduced pressure and the
 15 residue was chromatographed using 5% methanol saturated with ammonia 95%
 dichloromethane as the mobile phase over flash grade silica gel to yield 207 mg (95%)
 of a combined first-second intermediate, 1-2a, as a thick colorless oil.

Example 3Combined Third-Fourth Intermediates: The Coupling of Third and Fourth Component Pieces



5 The coupling of a third component piece with a fourth component piece provides a combined third-fourth intermediate. The combined third-fourth component piece is produced by amine bond formation resulting from the conjugate addition of the amine group of a fourth component piece 4 to the α,β -unsaturated carbonyl group of a third component piece 3.

10 The coupling of third and fourth component pieces provides, after deprotection, a combined third-fourth intermediate having the following structure 3-4:

3-4

where R₁, R₂, and R₅ are as described above (in this example, n of structure (I') is O).

15 The preparation of a combined third-fourth intermediate is accomplished by amine bond formation between the primary amino group of a fourth component piece 4 and α,β -unsaturated carbonyl group of a third component piece 3 followed by O-deprotection. The synthesis of a representative combined third-fourth intermediate is depicted schematically below.



3-4a


In the procedure, to 5 g of tyramine suspended in 40 ml freshly distilled tetrahydrofuran (THF) in an argon charged, 250 ml round-bottom flask was added methanol sufficient to dissolve the suspension. To the resulting solution was added 5.3 ml (4.67 g, 36.4 mmol) of t-butylacrylate dropwise over the course of 5 min, and the resulting reaction mixture was stirred overnight at room temperature. An additional 2 ml of t-butylactylate was added to consume the remaining starting material and the reaction was stirred an additional 4 hrs. Volatiles were removed under reduced pressure and the residue was chromatographed using 95:5 dichloromethane:ammonia saturated 5 methanol:NH₃/MeOH as the mobile phase over flash grade silica gel to yield 6.6 g (68%) of the ester, a colorless oil which solidified upon overnight refrigeration. To a solution of 1 gram (3.77 mmol) of the ester in 20 ml dichloromethane at 0°C was added 10 80 ml of cold trifluoroacetic acid (TFA) and the resulting reaction mixture was stirred with warming to room temperature over the course of 24 hrs. Volatiles were removed 15 under reduced pressure to yield 950 mg of a clear oil. The end product was dissolved in

95:5 dichloromethane:methanol and slowly filtered through a pad of neutral alumina. Volatiles were removed from the filtrate to yield 750 mg of 3-4a as an amorphous solid.

Example 4

5 Combined First-Second-Third-Fourth Intermediates: The Coupling of Combined First-Second and Third-Fourth Intermediates

The coupling of a combined first-second intermediate with a combined third-fourth intermediate provides a combined first-second-third-fourth intermediate. The 10 combined first-second-third-fourth intermediate is produced by amide bond formation resulting from the coupling of the amine group of a combined first-second intermediate 1-2 to the carboxylic acid group of a combined third-fourth intermediate 3-4. The combined first-second-third-fourth intermediate has the following structure 1-2-3-4:





1 - 2 - 3 - 4

15

where R, R₁, R₂, R₃, R₄ and R₅ are as described above.

The synthesis of a representative combined first-second-third-fourth intermediate is depicted schematically below.




In the procedure, 212 mg (1.0 mmol) 3-4a, 270 mg (1.01 mmol) 1-2a, and 136 mg (1.01 mmol) 1-hydroxybenzotriazole hydrate (HOBT) were dissolved in 10 ml dimethylformamide (DMF) and cooled to 0°C. To this solution was added 290 mg 5 (1.52 mmol, 1.5 eq) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) and the resulting reaction mixture was stirred and warmed to room temperature over the course of 24 hours. The DMF was removed under reduced pressure and the residue was redissolved in 200 ml ethyl acetate. The ethyl acetate layer was washed with saturated aqueous sodium bicarbonate, water, and dried over anhydrous sodium sulfate. Volatiles

were removed under reduced pressure and the residue was chromatographed using 95:5 dichloromethane: ammonia saturated methanol as eluent over flash-grade silica gel to yield 310 mg (0.68 mm 67%) 1-2-3-4a as a thick colorless oil.

5

Example 5The Synthesis of a Representative Reverse-Turn Mimetic: Cyclization of a Combined First-Second-Third-Fourth Intermediate

10 The cyclization of a combined first-second-third-fourth intermediate provides a reverse-turn mimetic of the present invention. The combined first-second-third-fourth intermediate 1-2-3-4 is cyclized by treatment with camphorsulfonic acid (CSA) or, in a preferred embodiment, TMSOTF (at 0°C) to provide a reverse-turn mimetic having the following structure (Ia):





15

(Ia)

where R₁, R₂, R₃, R₄, and R₅ are as described above.

The synthesis of a representative reverse-turn mimetic of the present invention is depicted schematically below.

20

Ia

In the procedure, 0.5 g (2.4 mmol) camphorsulfonic acid (CSA) was azeotroped with 3-15 ml portions of freshly distilled toluene and dried under vacuum at 40°C for 3 hrs in a 100 ml round-bottom flask equipped with a reflux condenser. Then 20 ml of freshly distilled toluene was added and the CSA solution was heated to a vigorous reflux. To this refluxing CSA solution was added a solution of 50 mg (0.11 mmol) 1-2-3-4a in 20 ml of freshly distilled toluene by syringe pump over the course of 1 hr. The resulting reaction mixture was refluxed for 12 hrs, cooled to room temperature and

diluted to 200 ml ethylacetate. The organic layer was washed with 2-75 ml portions of saturated aqueous sodium bicarbonate, 75 ml saturated aqueous sodium chloride, and dried over anhydrous sodium sulfate. Volatiles were removed under reduced pressure to yield 22 mg of 1a as a glassine solid. The crude product was triturated with 50/50 diisopropyl ether:hexane to remove non-polar impurities. The solid was then dissolved in dichloromethane and filtered to remove polar impurities. The residue upon evaporation was dried *in vacuo* for 24 hrs.

Example 6

10 Synthesis of a Representative Reverse-Turn Mimetic Salt

The reverse-turn mimetics of the present invention are nitrogen bases and may, therefore, be converted to their corresponding salts by treatment with various acids. In this example, the preparation of a representative salt of a reverse-turn mimetic is described.


The 2,4-dinitrobenzoic acid salt of reverse-turn mimetic 1a, prepared as described in Example 5, was obtained by treatment of the reverse-turn mimetic with the acid in aqueous methanol. In the procedure, 5 mg (12.7 μ mol) 1a was dissolved in 3 ml of 80/20 methanol:water and cooled to 0°C. To this solution was added 2.70 mg (12.7 μ mol, 1.0 eq) 2,4 dinitrobenzoic acid, and the resulting solution stirred until it became homogenous. Volatiles were removed under reduced pressure and the residue was dried *in vacuo* for 24 hrs. The residue was taken up in warm water and filtered to remove insoluble impurities. The solution was then lyophilized to give the salt, 5.

25

Example 7 Synthesis of a Representative Reverse-Turn Mimetics

30 This example illustrates the synthesis of further representative reverse-turn mimetics of this invention.


Synthesis of structure (6):



(6)


To a stirred solution of N-benzylglycine ethyl ester (1.93 g, 10 mmol) in THF (50 mL) was added Boc-Ala-OH (1.9 g, 10 mmol), followed by HOBr (1.62 g, 12 mmol) and EDCI (2.3 g, 12 mmol) at room temperature ("rt"). The resulting solution was stirred at rt for 5 hours ("h"). After dilution with EtOAc (100 mL), the solution was washed with 1N HCl (50 mL), sat. NaHCO₃ (50 mL), and brine (50 mL); it was dried (MgSO₄), passed through a short pad of SiO₂, and concentrated to give an oil in quantitative yield. TLC showed that the product was pure enough for use in the next reaction without further purification. TLC R_f 0.6 (hexane:EtOAc =5:5); ¹H NMR (CDCl₃) {the spectrum was assigned as 2:1 mixture of rotamers} δ 1.24 (two t, 3H, J=6.5 Hz), 1.35 and 1.36 (two d, 3H, J=6.5Hz), 1.42 and 1.43 (two s, 9H), 3.80 (dd, 1H, J=18Hz), 4.15 (q, 2H, J=6.5 Hz), 4.40 (dd, 1H), 4.65 (ABq, 2H, J=16.5 Hz), 4.80 (m, 1H), 5.40 (two d, 1H, J=8Hz, NH), 7.1-7.3 (m, 5H, phenyl); MS ES+ 365.1 (M+H⁺).

15


Synthesis of structure (7):

5

To a stirred solution of 3.8 g of crude ethyl ester (6) in THF/H₂O (50/50 mL) was added LiOH·H₂O (1g) at rt. After 30 min stirring at rt, the solution was washed with Et₂O (50 mL) and aqueous phase was acidified by 6N HCl (pH 2), and extracted with EtOAc (3×100 mL). The combined organic extracts were dried (MgSO₄), passed through a short pad of SiO₂, and concentrated to provide a foam in quantitative yield. The product was used for the next reaction without further purification. ¹H NMR (CDCl₃) {mixture of rotamers} δ 1.33 (two d, 3H, J=7 Hz), 1.41 (two s, 9H), 3.8-4.8 (set of m, 5H), 5.70 (two d, 1H, J=8Hz, NH), 7.2-7.6 (m, 5H, phenyl).


15 Synthesis of structure (8):

20 To a stirred solution of 3.4 g of acid (7) and cyanomethylene triphenylphosphorane (4.1 g, 12 mmol) in dichloromethane (100 mL) was added sequentially DIEA (5 mL, 30 mmol), DMAP (250 mg, 2 mmol), and EDCI (2.9 g, 15 mmol) at rt. After 12 h stirring, the solution was concentrated, and the resulting residue was taken up in 1N HCl (100 mL) and extracted with EtOAc (3×100 mL). The 25 combined extracts were washed with sat. NaHCO₃ (100 mL), dried (MgSO₄), passed through a short pad of SiO₂, and concentrated. The crude product was purified by flash chromatography (hexane:EtOAc = 50:50 to 30:70 to 20:80) to provide a foamy solid (4.40g, 71%). TLC R_f 0.5 (EtOAc); ¹H NMR (CDCl₃) {mixture of rotamers} δ 1.28 (two d, 3H, J=6.5 Hz), 1.44 (two s, 9H), 4.2-4.7 (set of m, 5H), 5.5 (two d, 1H, J=8Hz, 30 NH), 7.2 (m, 5H), 7.5 -7.8 (m, 15H); MS ES+ m/z 520.3, 620.3 (M+H⁺).

Synthesis of structure (9):

5

To a stirred solution of the phosphorane (8) (310 mg, 0.5 mmol) in dichloromethane (5 mL) was bubbled O₃ at -78°C for 15 min until solution became greenish blue; TLC showed complete consumption of the starting material. After bubbling Ar to remove excess ozone from this solution, N-benzylglycine ethyl ester 10 (100 mL) was added, and the solution was stirred at -78°C for 30 min. After concentration, the residue was dissolved in EtOAc (50 mL), washed with 1N HCl (20 mL), sat. NaHCO₃ (20 mL), brine (20 mL), dried (MgSO₄), and concentrated again. The crude product was purified by flash chromatography (hexane:EtOAc = 90:10 to 15 80:20 to 70:30 to 60:40) to provide an oil (105 mg, 39%). TLC R_f 0.42 (hexane:EtOAc = 60:40); ¹H NMR (CDCl₃) {the spectrum was assigned as a 1:1 mixture of rotamers} δ 1.25 (two t, 3H, J=7Hz), 1.31 and 1.38 (two d, 3H, J=7Hz), 1.41 and 1.43 (two s, 9H), 3.8-4.8 (set of m, 11H), 5.5 (two d, 1H, NH), 7.2-7.4 (m, 5H). MS ES+ m/z 440.3, 540.3 (M+H⁺).


20 Synthesis of structure (10):

25 A solution of 100 mg ketoamide (9) (0.18 mmol) in 0.5 mL dichloromethane was treated with 0.5 mL TFA at rt for 30 min. After concentration, the residue was dissolved in MeOH (2 mL) and treated with ZnCl₂ (6 mg) and NaBH₃CN (15 mg) at rt for overnight (13h). After concentration, the residue was taken up in sat. NaHCO₃ (20 mL), extracted with EtOAc (2×20 mL). The combined organic extracts were dried 30 (MgSO₄), concentrated to an oil, and purified by preparative TLC (hexane:EtOAc=60:40) to provide a glassy solid (52 mg, 77%). (The enamine proved

resistant to reduction by this method.) TLC R_f 0.58 (EtOAc); 1H NMR (CDCl₃) δ 1.41 (d, 3H, J =6.5Hz, CHCH₃), 3.93 (ABq, 2H, J =18Hz, CH₂ in Gly), 4.46 and 4.75 (ABq, 1H each, J =14.5Hz, CH₂Ph), 4.76 (ABq, 2H, J =14Hz, CH₂Ph), 5.22 (q, 1H, J =7Hz, CHCH₃), 6.83 (s, 1H, =CH), 7.33 (m, 10H, phenyls); ^{13}C NMR (CDCl₃) δ 16.63, 49.59, 5 49.66, 49.84, 50.98, 111.92, 119.16, 128.07, 128.22, 128.29, 128.52, 128.94, 128.97, 134.78, 134.43, 157.96, 160.67, 165.33. MS ES+ m/z 376.3 (M+H⁺).

Synthesis of structure (11):

10



A solution of 25 mg structure (10) (0.066 mmol) with PtO₂ (5 mg) in MeOH (2 mL) was stirred under H₂ atmosphere (20 atm) for 10 days. After concentration, the 15 residue was purified by preparative TLC (hexane:EtOAc = 60:40 to 50:50) to yield a pale yellow oil (14 mg, 56%) with starting material (10 mg). TLC R_f 0.49 (EtOAc); 1H NMR (CDCl₃) δ 1.14 (d, 1.5H, J =7 Hz, CHCH₃), 1.52 (d, 1.5H, J =7 Hz, CHCH₃), 3.2-4.8 (set of m, 10H), 7.33 (m, 10H, phenyls); MS ES+ m/z 378 (M+H⁺). RP-HPLC analysis: C-18; A: 0.1% TFA (aq); B 0.1% TFA (CH₃CN); gradient: 0-90%/40'; 254 20 nm tR 24.1' and 24.7' showed a 2:1 ratio.

Example 8

Synthesis of a Representative

Reverse-Turn Mimetics

25

This example further illustrates the syntheses of reverse-turn mimetics of this invention. Specifically, the preparation of [4.4.0] bicyclic reverse-turn mimetics was carried out in solution phase (Method A) and on solid phase (Methods B and C). Structures of representative mimetics are given in Table 2. The solid phase syntheses 30 of these reverse-turn mimetics demonstrate that libraries containing such members may be readily prepared.


Method A solution phase synthesis is analogous to the solid phase synthesis of Method B and was carried out essentially as illustrated in Figure 2. The compounds were purified as in Method C, below.

The solid phase synthesis of Method B is illustrated in Figure 8. Referring to 5 that figure, commercially available aminomethyl resin was reacted with excess 4-bromo-2-butenoic acid and DIC (diisopropylcarbodiimide) in DMF to give 4-bromo-2-butenoamide resin. Substitution of the bromo group with a primary amine in DMSO gave the corresponding 4-alkylamino-2-butenoamide resin. Standard peptide coupling procedures on solid phase were performed to give N-alkyloxycarbonyl- α -alkyl- β -10 alanyl- α -alkylglycyl-N'-alkylamino-2-butenoamide resin. The reverse-turn mimetics were obtained by osmium tetroxide catalyzed periodate oxidation of the resin followed by the treatment of the resulting monocyclic product with a catalytic amount of TFA in dichloromethane. The crude products gave a single major peak by reverse-phase HPLC analysis.

15 The solid phase synthesis of Method C is similar to Method B and is given in Example 11 and illustrated in Figure 9. Selected compounds were purified by flash chromatography or preparative TLC on silica gel using suitable combinations of EtOAc and MeOH.

The mimetics were characterized as follows: Analytical C₁₈ reverse-phase 20 HPLC was carried out using standard techniques (mobile phase: gradients of 0.1% in water and acetonitrile. By these methods, crude products synthesized on solid phase generally displayed purities of greater than 80%, and all purified compounds greater than 95%. Electrospray mass spectrometry was carried out using standard techniques. The observed value of the (M+H⁺) ion is given for each compound in Table 2. ¹H 25 NMR was carried out on purified mimetics and spectra were assigned by a combination of COSY and ROESY experiments. All spectra were consistent with the structures indicated below, and displayed a conformation similar to a type I or type II β -turn.

Table 2
Representative Reverse-Turn Mimetics



5

No.	R	R ₂	R ₃	R ₄	Method	MS
						(MH ⁺)
12	Bn	H	Me	Me	A, B	332
13	<i>p</i> -MeO-Ph(CH ₂) ₂	H	H	Bn	A	438
14	<i>p</i> -MeO-Ph(CH ₂) ₂	H	H	Phenethyl	A	452
15	<i>p</i> -OH-Ph(CH ₂) ₂	H	H	Phenethyl	A	438
16	<i>p</i> -OH-Ph(CH ₂) ₂	H	Bn	Pentyl	A	494
17	<i>i</i> -Bu	H	(CH ₂) ₂ CO ₂ H	<i>i</i> Bu	A	398
18	<i>i</i> -Bu	H	CH ₂ CO ₂ H	<i>i</i> Bu	A	384
19	<i>i</i> -Bn	Bn	Bn	Pentyl	A	554
20	Bn	H	Me	Bn	B	408
21	Bn	H	Bn	Bn	B	484
22	Bn	H	Me	<i>n</i> -Bu	B	374
23	Bn	H	Bn	<i>n</i> -Bu	B	449
24	Bn	H	Me	<i>i</i> -Amyl	B	388
25	Bn	H	Bn	<i>i</i> -Amyl	B	469
26	Bn	H	Bn	<i>p</i> -Cl-Bn	C	518
27	Bn	Ac-NH	Me	Me	C	389
27	Bn	Bz-NH	Me	Me	C	451
29	<i>p</i> -OH-Ph(CH ₂) ₂	H	Bn	Phenethyl	C	515
30	<i>p</i> -OH-Ph(CH ₂) ₂	H	Phenethyl	Pentyl	C	508
31	<i>p</i> -OH-Ph(CH ₂) ₂	H	Bn	2-Pyr(CH ₂) ₂	C	529
32	Bn	H	<i>t</i> -BuO ₂ C-(CH ₂) ₂	Me	B	446
33*	Ph	H	Bn	c.HexCH ₂	C	496
34*	Ph	Ac-NH	Me	Me	C	395
35*	<i>p</i> -Tolyl	H	Bn	<i>p</i> -Cl-Bn	C	538

36	<i>p</i> -OH-Ph(CH ₂) ₂	H	H	Pentyl	C	404
37	<i>p</i> -OH-Ph(CH ₂) ₂	H	Me	Pentyl	C	418
38	<i>p</i> -OH-Ph(CH ₂) ₂	H	MeS(CH ₂) ₂	Pentyl	C	478
39	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>i</i> -Bu	Pentyl	C	460
40	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>i</i> -Pr	Pentyl	C	446
41	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>s</i> -Bu	Pentyl	C	460
42	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>p</i> -OH-PhCH ₂	Pentyl	C	510
43	<i>p</i> -OH-Ph(CH ₂) ₂	H	Ph	Pentyl	C	480
44	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>p</i> -Cl-PhCH ₂	Pentyl	C	528
45	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>p</i> -NH ₂ -PhCH ₂	Pentyl	C	509
46	<i>p</i> -OH-Ph(CH ₂) ₂	H	Bn	MeO(CH ₂) ₃	C	496
47	<i>p</i> -OH-Ph(CH ₂) ₂	H	Bn	<i>i</i> -Amyl	C	494
48	<i>p</i> -OH-Ph(CH ₂) ₂	H	Bn	Heptyl	C	522
49	<i>p</i> -OH-Ph(CH ₂) ₂	H	Bn	Bn	C	514
50	<i>p</i> -OH-Ph(CH ₂) ₂	H	Bn	c.Hex CH ₂	C	520
51	<i>p</i> -OH-Ph(CH ₂) ₂	H	Bn	4-PyrCH ₂	C	515
52	<i>p</i> -OH-Ph(CH ₂) ₂	H	Bn	<i>i</i> -Bu	C	480
53	<i>p</i> -OH-Ph(CH ₂) ₂	H	Bn	3,4-MeO- Phenethyl	C	588
54	<i>p</i> -OH-Ph(CH ₂) ₂	H	Bn	N-Pyridone- (CH ₂) ₃	C	549
55	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>p</i> -OH-PhCH ₂	MeO(CH ₂) ₃	C	512
56	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>p</i> -OH-PhCH ₂	<i>i</i> -Amyl	C	510
57	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>p</i> -OH-PhCH ₂	Heptyl	C	538
58	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>p</i> -OH-PhCH ₂	Bn	C	530
59	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>p</i> -OH-PhCH ₂	c.Hex CH ₂	C	536
60	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>p</i> -OH-PhCH ₂	4-PyrCH ₂	C	531
61	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>p</i> -OH-PhCH ₂	<i>i</i> -Bu	C	496
62	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>p</i> -OH-PhCH ₂	3,4-MeO- Phenethyl	C	604
63	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>p</i> -OH-PhCH ₂	N-Pyridone- (CH ₂) ₃	C	565
64	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>p</i> -OH-PhCH ₂	Phenethyl	C	544
66	<i>p</i> -OH-Ph(CH ₂) ₂	H	Phenethyl	Phenethyl	C	529
67	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>p</i> -OH-PhCH ₂	2-Pyr(CH ₂) ₂	C	545
68	<i>p</i> -OH-Ph(CH ₂) ₂	H	Phenethyl	2-Pyr(CH ₂) ₂	C	543

69	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>i</i> -Pr	<i>i</i> .Amyl	C	446
70	<i>p</i> -OH-Ph(CH ₂) ₂	H	<i>i</i> -Bu	<i>i</i> .Amyl	C	460

*-SO₂- replaces -OC(O)- in the R₁ side chain in this compound.

Example 9

5 Activity of a Representative Reverse-Turn Mimetic in Opioid Receptor Binding

In this example, the binding activity of representative reverse-turn mimetics to the delta (δ) and mu (μ) opioid receptors as well as to a preparation of non-selective opioid receptors is described. The binding affinity of 5, the 2,4-dinitrobenzoic acid salt of reverse-turn mimetic of structure Ia (prepared as described in Example 6), and a variety of reverse-turn mimetics prepared as described in Example 8, was evaluated in these competitive radioligand binding assays.

15 A. Opiate (δ) Binding Activity

In this method, membranes were prepared from whole brains of male guinea pigs and equilibrated with 2 nM [3 H]DPDPE (D-pen³, D-pen⁵) enkephalin for 1 hour at 4°C after which test substances were added and incubated for 4 hours at 25°C. Non-specific binding was determined in the presence of 0.3 μ M naltrindole. Bound [3 H]DPDPE was separated from free radioligand by rapid filtration through glass fiber filtermats and subsequently washed 3 times. Filtermats were then counted in the LKB Betaplate to determine specifically bound [3 H]DPDPE. (See Mosberg et al., "Structural Requirements for δ Opiate Receptor Binding," *Molec. Pharmacol.* 31:599-602, 1987.)

25 Table 3
Effect of Reference Compounds on [³H]DPDPE Bound (2nM)

Compound	IC ₅₀ (nM)	Ki (nM)	Hill Coefficient
DAMGO	4,800	1,200	1.08
DPDPE	5.5	1.3	0.86
Naltrindole	0.63	0.20	0.53
U-50488	53,000	16,000	0.73

In this assay, the radioligand, [³H]DPDPE, was determined to have a K_d = 0.65 nM with a B_{max} = 12.6 fmol/mg protein and a specific binding of 60%. At a

concentration of 10 μ M, 5 was found to inhibit radioligand binding at the 60% level, and exhibited a $K_i = 1.7 \pm 0.3 \mu$ M and an $IC_{50} = 6.9 \pm 1.2 \mu$ M. These results are presented in Figure 1 (o) which depicts the % inhibition of radioligand binding as a function of reverse-turn mimetic 5 concentration. Also, at a concentration of 10 μ M, 5 reverse-turn mimetic 16 was found to inhibit radioligand binding at the 92% level. These results demonstrate that reverse-turn mimetics 5 and 16, in particular, and the reverse-turn mimetics of the present invention, in general, effectively inhibit binding to the δ opiate receptor, and possess analgesic activity.

10 B. Opiate (μ) Binding Activity

In this method, membranes were prepared from whole brains of male guinea pigs and incubated with 2 nM [3 H]DAMGO (D-Ala², N-methyl-phe⁴, gly-ol⁵)-enkephalin) for 2 hours at 25°C. Non-specific binding was determined in the presence of 0.5 μ M DAMGO. Bound [3 H]DAMGO was separated from free radioligand by 15 rapid filtration through glass fiber filtermats and subsequently washed 3 times. Filtermats were then counted in the LKB Betaplate to determine specifically bound [3 H]DAMGO. (See Patricia et al., "Pharmacological profiles of fentanyl analogs at μ , δ and κ opiate receptors," *Eur. J. Pharmacol.* 213:219-225, 1992.)

20

Table 4
Effect of Reference Compounds on [3 H]DAMGO Bound (2nM)

Compound	IC_{50} (nM)	K_i (nM)	Hill Coefficient
DAMGO	6.5	0.59	0.92
DPDPE	4.0	0.37	1.32
Fentanyl	14	1.2	0.99
Naloxone	9.3	0.76	1.09
Naltrindole	27	2.5	0.98
Norbinaltorphimine	280	26	1.13
U-50488	6.1	0.59	0.70

In this assay, the radioligand, [3 H]DAMGO, was determined to have a 25 $K_d = 0.27$ nM with a $B_{max} = 8.7$ pmol/mg protein and a specific binding of 70%. At a concentration of 10 μ M, 5 inhibited radioligand binding at the 64% level, and exhibited a $K_i = 0.64 \pm 0.08 \mu$ M and an $IC_{50} = 5.4 \pm 0.7 \mu$ M. These results are presented in

Figure

1

(•) which depicts the % inhibition of radioligand binding as a function of reverse-turn mimetic 5 concentration. Also, at a concentration of 10 μ M, reverse-turn mimetic 16 was found to inhibit radioligand binding at the 98% level. These results demonstrate 5 that reverse-turn mimetics 5 and 16, in particular, and the reverse-turn mimetics of the present invention, in general, effectively inhibit binding to the μ opiate receptor, and possess analgesic activity.

C. Opiate (Non-selective) Binding Activity

10 In this method (Childers et al. *Eur. J. Pharmacol.* 55: 11, 1979), membranes were prepared from rat cerebral cortex and incubated with [3 H]naloxone (1 nM) and β -turn mimetics (30 μ M – 0.3 nM) for 40 min at 22 °C. Following incubation, the membranes were rapidly filtered under vacuum through glass fiber filters (Filtermat A, Wallac). The filters were then washed several times with an ice-cold buffer using a 15 cell harvester (Tomtec). Bound radioactivity was measured with a scintillation counter (Betaplate, Wallac) using solid scintillant (MultiLex B/HS, Wallac). In same experiment, the reference compound (naloxone) was tested at eight concentrations in duplicate to obtain a competition curve in order to validate this experiment.

20 The specific radioligand binding to the receptors is defined as the difference between total binding and nonspecific binding determined in the presence of an excess of unlabelled ligand. Results were expressed as a percent of control specific binding obtained in the presence of β -turn mimetics. IC_{50} values and Hill coefficients (nH) were determined by non-linear regression analysis of the competition curves. These parameters were obtained by Hill equation curve fitting. The inhibition constants 25 (K_i) were calculated from the Chen Prusoff equation ($K_i = IC_{50}/(1+L/K_d)$, where, L = concentration of radioligand in the assay, and K_d = affinity of the radioligand for the receptor).

30 In this assay, the radioligand, [3 H]naloxone, was determined to have an $IC_{50} = 2.5$ nM. Reverse turn mimetics, prepared and purified as described in Example 8, displayed specific binding of up to 99% at 1 μ M concentration. Compounds 29 and 30 were determined to have IC_{50} s of 80 and 27 nM, respectively, with Hill coefficients of 0.9. These results demonstrate the mimetics 29 and 30, in particular, and the reverse-turn mimetics of the present invention, in general, effectively inhibit binding to the opioid receptor (non-selective), and possess analgesic activity.

Example 10
In Vivo Activity of a Representative
Reverse-Turn Mimetic for Analgesic Activity

5 In this example, the *in vivo* activity of a representative reverse-turn mimetic as an analgesic agent is presented. Compound 5, prepared as described in Example 6 (hereinafter referred to as "test compound"), was utilized in the mouse tail flick assay (PanLabs, Pharmascreen Test No. 10402A). In this assay, the time required to elicit a tail-flick response to radiant heat pain stimulus in a group of mice is measured
10 as the pain threshold response.

Groups of five (3 test groups + 1 saline control + 1 morphine positive control) male ICR mice weighing 22 (± 2) grams each were used. Each of these animals were pre-selected and elicited a tail flick response within 6-7.5 seconds after a focused beam of radiant heat was focused on the middle dorsal surface of the animal's tail.
15 Specific amounts of the test compound (*i.e.*, 10, 30 and 100 μ g) were dissolved in 5 microliters (5 μ l) saline containing 6% DMSA and administered intracerebroventricularly (ICV) to each animal. A saline-only solution was used as a negative control, with an ICV injection of 10 μ g/5 μ l/animal of morphine serving as a positive control.

20 At one minute post-ICV injection, the groups of mice were measured for tail flick response, with a maximum cut-off time of 15 seconds. The mean of the response time for each treatment groups was calculated for a comparison between pre-treatment ("0 time") and 1 minute post-treatment ("1 min."). Prolongation 1 minute post-treatment of over 50% ("% Prolong.") was considered significant activity. The
25 results of this experiment are presented in Table 5, and demonstrate that the test compound had significant analgesic activity (*i.e.*, approximately 10%-15% the potency of morphine).

30 Table 5
In Vivo Tail Flick Assay

Compound	Dose/5 μ l	0 Time	1 Min.	% Prolong.
Saline	0	6.9	6.7	—
		6.9	7.5	—
		6.1	6.2	—
		6.5	6.3	—

		Avg.=6.6	Avg.=6.7	2%
Morphine	10 μ g	7.5	>15	--
		6.3	>15	--
		7.2	>15	--
		6.8	>15	--
		Avg.=7.0	Avg.>15	100%
Test Compound	100 μ g	6.5	>15	--
		6.3	>15	--
		6.5	>15	--
		6.8	>15	--
		Avg.=6.5	Avg.>15	100%
	30 μ g	6.5	>15	--
		6.7	7.2	--
		7.2	6.3	--
		6.3	>15	--
		Avg.=6.7	Avg.>15	63%
	10 μ g	6.5	7.5	--
		7.2	7.5	--
		6.9	6.7	--
		6.2	6.8	--
		Avg.=6.7	Avg.7.1	6%

Example 11


Synthesis of Representative
Reverse-Turn Mimetics

5

This example further illustrates the synthesis of reverse-turn mimetics of this invention. Specifically, the preparation of [4.4.0] bicyclic reverse-turn mimetics was carried out on solid phase by a method alternative to that of Example 8, method B. The method is outlined in Figure 9.

10

Synthesis of 2-Bromo-1-ethoxy-ethyl-1-oxy-linked Resin (27)



(27)

In general, a batch of resin (ArgogelOH or hydroxymethyl polystyrene) was refluxed in 1,2-dichloroethane (DCE) for 4 hours in the presence of 8 equivalents of bromoalkylaldehyde diethyl acetal and 2 equivalents of pyridinium p-toluenesulfonate (PPTS). In one instance, hydroxymethyl polystyrene (10.0 g, 0.7 mmol OH/g, 7 mmol) and 3.5 g of PPTS (14 mmol) were suspended in 200 ml of DCE. Then, a solution of 8.5 ml of 2-bromodiethoxyethane (ca. 56 mmol) in DCE (100 ml) was added with stirring and the reaction mixture was heated at reflux (approx. 80 °C). After 4 hours the resin was filtered off and washed with 100 mL dimethylformamide (DMF), 50 mL dimethylsulfoxide (DMSO), 100 mL DMF, 200 mL dichloromethane (DCM), 50 mL 1,4-dioxane and finally with 100 mL methanol. After drying, 11.73 g, of resin 27 was obtained. Bromine analysis indicated quantitative loading.

15 Synthesis of Representative Compounds of Structure (Ia')

Reactions were carried out in plastic disposable syringes of the appropriate size, each fitted with a polypropylene frit to retain the resin. After each step, resin batches were washed with DMF (3 \times) and DCM (3 \times). Typically, a 0.03 mmol sample of resin 27 (e.g., 50 mg of polystyrene resin with loading of 0.6 mmol Br/g), pre-swollen in DMF, was treated with 1 mL of a 2.0 M solution of amine $R_4\text{-NH}_2$ (2 mmol) in DMSO at 60°C for 16–24 hrs.

Next, the resin was reacted with 0.09 mmol of Fmoc amino acid (FmocNH-CHR₃-COOH) in the presence of HATU (34 mg, 0.09 mmol) and DIEA (0.032 ml, 0.18 mmol) in DMF (1 mL) until the chloranil test was negative (typically 1–2 h). Subsequently, the Fmoc protection was removed by treatment with a 25% (v/v) piperidine/DMF solution (2 mL) over 20 min.

The resin was then reacted with 0.09 mmol of an Fmoc beta-amino acid (FmocNH-CHR₅-CHR₂-COOH) in the presence of DIC (0.014 ml, 0.09 mmol) and HOBr (14 mg, 0.09 mmol) in DMF (1 mL) until the Kaiser test was negative (typically 1 hour). The resin was again treated with 25% (v/v) piperidine/DMF solution (2 mL) over 20 min.


Finally, the resin-bound sequence was terminated by reaction with sulfonyl chloride ($R_1\text{SO}_2\text{Cl}$, 0.3 mmol) in the presence of DIEA (0.106 mL, 0.6 mmol) in DCM (1 mL) for 1 hr (Kaiser test negative). Alternatively, chloroformate $R_1\text{OCOCl}$ or isocyanate $R_1\text{NCO}$ (the latter does not require presence of DIEA) was used instead of sulfonyl chloride for introduction of the R_1 moiety.

The washed and dried resin was re-swollen in DCM, drained and treated with 1 mL of formic acid (96%) overnight at rt. In a number of cases, an elevated temperature up to 60°C or an extended reaction time was necessary to complete the cyclization (for conditions see Table 2 below). The supernatant was collected and combined with washes (2×0.5 mL of formic acid). The residue obtained after evaporation of formic acid was redissolved in acetonitrile/water 50:50 mixture, frozen and lyophilized.

Table 6 presents representative compounds of this invention synthesized by the above procedure.

10

Table 6
Representative Reverse-Turn Mimetics



15

No.	R ₁	R ₂	R ₃	R ₄	R ₅	(M+H ⁺)
28						406.3
29						512.3
30						602.4
31						496.3
32						600.3
33						584.3

34						536.4
35					583.6	
36					597.6	
37					569.4	
38					583.4	
39					550.5	
40					495.3	

Example 12

Activity of Representative Reverse-Turn
Mimetics in a Cell Adhesion Assay

5

An assay measuring the ability of the compounds of Example 1 to antagonize binding of CS1 peptide to $\alpha_4\beta_1$ integrin was performed. A modification of the procedure of Vanderslice, P. et al. (*J. Immunol.*, 1997, 1710-1718) (incorporated 10 herein by reference) was utilized.


In brief, 100 μ L/well of a solution of biotinylated CS1 peptide (1 mg/100 mL of phosphate buffered saline (PBS)) was incubated in a NeutrAvidin plate (Pierce) for 1 h at room temperature. The plate was then washed 3 \times with distilled water and treated with 200 μ L of blocking buffer (3% BSA in PBS) for at least 4 h. Blocked 5 plates were washed as above. Harvested Ramos cells (10^7 /mL) were resuspended in PBS containing 10 μ L of calcein AM/mL and incubated 30 min in the dark. This suspension was diluted with 45 mL PBS and the cells harvested by centrifugation and aspiration. The cells were resuspended in binding buffer ($\sim 5 \times 10^5$ /mL). If cell lysis was to be monitored ethidium homodimer was added to the buffer to a final concentration of 10 5 μ M. A solution (10 μ L) of compound to be tested or control peptide was added to appropriate wells followed by 90 μ L of the cell suspension. The plate was incubated at 37 °C for 1 h. When ethidium homodimer was added, fluorescence at 535/617 was measured before rinsing. Otherwise, the plate was washed 3 \times , 50 μ L of lysis buffer was added to each well, the plate rocked in the dark for 10 min, and the fluorescence 15 monitored at 485 nm excitation and 535 nm emission.

Compounds prepared in Example 11 displayed activity in this assay. As such, the compounds of this invention effectively inhibit cell adhesion and possess activity as anti-inflammatory agents.

20 It will be appreciated that, although specific embodiments of the invention have been described herein for the purposes of illustration, various modifications may be made without departing from the spirit and scope of the invention. Accordingly, the invention is not limited except by the appended claims.

Claims

1. A method for treating a cell adhesion-mediated disease comprising administering to a warm-blooded animal in need thereof a composition comprising a therapeutically effective amount of a compound having the structure:



wherein

Y is selected from $-\text{CH}(\text{R}_5)\text{-A-N}(\text{R}_1)\text{-}$, $-\text{A-N}(\text{R}_1)\text{-CH}(\text{R}')\text{-}$, $-\text{A-N}(\text{R}_1)\text{-C(=O)}\text{-}$, $-\text{A-C(=O)}\text{-N}(\text{R}_1)\text{-}$, $-\text{A-CH}(\text{R}_1)\text{-O-}$ and $-\text{A-CH}(\text{R}_1)\text{-N}(\text{R}')\text{-}$;

A is $-(\text{CHR}')_n\text{-}$, where $n = 0, 1$ or 2 ;

B is $-(\text{CHR}'')_m\text{-}$, where $m = 1, 2$ or 3 ;


R' , R'' , R_2 , R_3 and R_5 are the same or different and independently selected from an amino acid side chain moiety or derivative thereof, a linker and a solid support; and

R_1 and R_4 represent the remainder of the compound; and

wherein any two adjacent CH groups or adjacent NH and CH groups on the fused bicyclic ring may optionally form a double bond;


in combination with a pharmaceutically acceptable carrier or diluent.

2. The method of claim 1 wherein Y is $-\text{CH}(\text{R}_5)\text{-A-N}(\text{R}_1)\text{-}$ and the compound has the structure:




wherein A, B and R_1 through R_5 are as recited in claim 1.

3. The method of claim 2 wherein A is $-(CH_2)_n-$, B is $-(CH_2)_m-$ and the compound has the structure:




wherein n, m and R₁ through R₅ are as recited in claim 1.

4. The method of claim 3 wherein n is 0, m is 1 and the compound has the structure:




wherein R₁ through R₅ are as recited in claim 1.

5. The method of claim 1 wherein Y is $-A-N(R_1)-CH(R')-$ and the compound has the structure:




wherein A, R' and R₁ through R₄ are as recited in claim 1.

6. The method of claim 5 wherein two adjacent CH groups on the fused bicyclic ring form a double bond and the compound has the structure:




wherein A, B, R' and R₁ through R₄ are as recited in claim 1.

7. The method of claim 6 wherein A is -(CH₂)_n-, B is -(CH₂)_m-, R' is hydrogen and the compound has the structure:




wherein n, m and R₁ through R₄ are as recited in claim 1.

8. The method of claim 1 wherein Y is -A-N(R₁)-C(=O)- and the compound has the structure:




wherein A, B and R₁ through R₄ are as recited in claim 1.

9. The method of claim 8 wherein A is -(CH₂)_n-, B is -(CH₂)_m and the compound has the structure:




wherein n, m and R₁ through R₄ are as recited in claim 1.

10. The method of claim 1 wherein Y is -A-C(=O)-N(R₁)- and the compound has the structure:




wherein A, B and R₁ through R₄ are as recited in claim 1.

11. The method of claim 10 wherein A is -(CH₂)_n-, B is -(CH₂)_m- and the compound has the structure:




wherein n, m and R₁ through R₄ are as recited in claim 1.

12. The method of claim 1 wherein Y is -A-CH(R1)-O- and the compound has the structure:




wherein A, B and R₁ through R₄ are as recited in claim 1.

13. The method of claim 12 wherein A is -(CH₂)_n-, B is -(CH₂)_m- and the compound has the structure:




wherein n, m and R₁ through R₄ are as recited in claim 1.

14. The method of claim 1 wherein Y is -A-CH(R₁)-N(R')- and the compound has the structure:




wherein A, B, R' and R₁ through R₄ are as recited in claim 1.

15. The method of claim 14 wherein two adjacent NH and CH groups on the fused bicyclic ring form a double bond and the compound has the structure:



wherein A, B and R₁ through R₄ are as recited in claim 1.

16. The method of claim 15 wherein A is -(CH₂)_n-, B is -(CH₂)_m- and the compound has the structure:



wherein n, m and R₁ through R₄ are as recited in claim 1.

17. The method of claim 1 wherein the compound is an inhibitor of $\alpha_4\beta_1$ integrin or $\alpha_4\beta_7$ integrin.

18. The method of claim 1 wherein the cell adhesion-indicated disease is rheumatoid arthritis, Alzheimer's disease, AIDS dementia, ARDS, asthma, allergies, inflammatory bowel disease, CNS inflammation, atopic dermatitis, encephalitis, multiple sclerosis, meningitis, nephritis, type I diabetes, atherosclerosis, myocardial ischemia, restenosis, stroke, tumor metastasis, retinitis or psoriasis.

19. The method of claim 18 wherein the cell adhesion-indicated disease is atherosclerosis, asthma, inflammatory bowel disease, multiple sclerosis.

20. The method of claim 18 wherein the cell adhesion-indicated disease is atherosclerosis.

21. The method of claim 18 wherein the cell adhesion-indicated disease is asthma.
22. The method of claim 18 wherein the cell adhesion-indicated disease is inflammatory bowel disease.
23. The method of claim 18 wherein the disease is multiple sclerosis.




Figure 1




Figure 2




Figure 3




Figure 4





Figure 5

*Figure 6*




Figure 7




Figure 8




Figure 9

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 00/17053

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/4985 A61K31/519 C07D487/04 C07D498/04 C07K5/06 A61P9/00 A61P29/00																							
According to International Patent Classification (IPC) or to both national classification and IPC																							
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K C07D C07K																							
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																							
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal																							
C. DOCUMENTS CONSIDERED TO BE RELEVANT <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left; padding: 2px;">Category</th> <th style="text-align: left; padding: 2px;">Citation of document, with indication, where appropriate, of the relevant passages</th> <th style="text-align: right; padding: 2px;">Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; padding: 2px;">Y</td> <td style="padding: 2px;">WO 98 49168 A (MOLECUMETICS LTD.) 5 November 1998 (1998-11-05) cited in the application the whole document ----</td> <td style="text-align: right; padding: 2px;">1-21</td> </tr> <tr> <td style="text-align: center; padding: 2px;">Y</td> <td style="padding: 2px;">WO 98 05333 A (MOLECUMETICS LTD.) 12 February 1998 (1998-02-12) claims 1-16 ----</td> <td style="text-align: right; padding: 2px;">1-21</td> </tr> <tr> <td style="text-align: center; padding: 2px;">Y</td> <td style="padding: 2px;">WO 97 15577 A (MOLECUMETICS LTD.) 1 May 1997 (1997-05-01) cited in the application the whole document ----</td> <td style="text-align: right; padding: 2px;">1-21</td> </tr> <tr> <td style="text-align: center; padding: 2px;">Y</td> <td style="padding: 2px;">WO 96 30396 A (MOLECUMETICS LTD.) 3 October 1996 (1996-10-03) claim 146 ----</td> <td style="text-align: right; padding: 2px;">1-21</td> </tr> <tr> <td></td> <td style="text-align: center; padding: 2px;">-/-</td> <td></td> </tr> </tbody> </table>						Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	Y	WO 98 49168 A (MOLECUMETICS LTD.) 5 November 1998 (1998-11-05) cited in the application the whole document ----	1-21	Y	WO 98 05333 A (MOLECUMETICS LTD.) 12 February 1998 (1998-02-12) claims 1-16 ----	1-21	Y	WO 97 15577 A (MOLECUMETICS LTD.) 1 May 1997 (1997-05-01) cited in the application the whole document ----	1-21	Y	WO 96 30396 A (MOLECUMETICS LTD.) 3 October 1996 (1996-10-03) claim 146 ----	1-21		-/-	
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																					
Y	WO 98 49168 A (MOLECUMETICS LTD.) 5 November 1998 (1998-11-05) cited in the application the whole document ----	1-21																					
Y	WO 98 05333 A (MOLECUMETICS LTD.) 12 February 1998 (1998-02-12) claims 1-16 ----	1-21																					
Y	WO 97 15577 A (MOLECUMETICS LTD.) 1 May 1997 (1997-05-01) cited in the application the whole document ----	1-21																					
Y	WO 96 30396 A (MOLECUMETICS LTD.) 3 October 1996 (1996-10-03) claim 146 ----	1-21																					
	-/-																						
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.			<input checked="" type="checkbox"/> Patent family members are listed in annex.																				
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed																							
T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family																							
Date of the actual completion of the international search		Date of mailing of the international search report																					
17 November 2000		11/12/2000																					
Name and mailing address of the ISA			Authorized officer																				
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016			Kyriakakou, G																				

INTERNATIONAL SEARCH REPORT

Inte	onal Application No
PCT/US 00/17053	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 22304 A (MOLECUMETICS, LTD) 25 July 1996 (1996-07-25) the whole document ---	1-21
A	WO 94 03494 A (THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS) 17 February 1994 (1994-02-17) the whole document ---	1-21
A	WO 92 13878 A (BOARDS OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS) 20 August 1992 (1992-08-20) the whole document ---	1-21
Y	THOMAS W. KU ET AL.: "Direct Design of a Potent Non-Peptide Fibrinogen Receptor Antagonist Based on the Structure and conformation of aHighly constrained Cyclic RGD Peptide" JOURNAL OF AMERICAN CHEMICAL SOCIETY, vol. 115, no. 19, 22 September 1993 (1993-09-22), pages 8861-8862, XP002153184 COLUMBUS OHIO the whole document ---	1-21
Y	ANDREW J. SOUERS ET AL.: "Novel Inhibitors of a4b1 integrin receptor interactions through library synthesis and screening" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , vol. 8, 1998, pages 2297-2302, XP004138221 cited in the application the whole document ---	1-21
Y	DAVID Y. JACKSON ET AL.: "Potent a4b1 Peptide Antagonists as Potential Anti-inflammatory Agents" JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, no. 21, 1997, pages 3359-3368, XP002148351 columbus ohio cited in the application the whole document ---	1-21

INTERNATIONAL SEARCH REPORT

Information on patent family members !

International Application No

PCT/US 00/17053

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9849168	A 05-11-1998	US 6013458 A		11-01-2000
		AU 7167998 A		24-11-1998
		EP 0980373 A		23-02-2000
WO 9805333	A 12-02-1998	AU 3905897 A		25-02-1998
		EP 0915700 A		19-05-1999
		NO 990522 A		30-03-1999
		US 6117896 A		12-09-2000
WO 9715577	A 01-05-1997	US 5929237 A		27-07-1999
		AU 719620 B		11-05-2000
		AU 7520596 A		15-05-1997
		EP 0876371 A		11-11-1998
		JP 11513986 T		30-11-1999
		US 6013458 A		11-01-2000
WO 9630396	A 03-10-1996	AU 712581 B		11-11-1999
		AU 5371496 A		16-10-1996
		AU 713530 B		02-12-1999
		AU 5372996 A		16-10-1996
		CA 2215695 A		03-10-1996
		CA 2215720 A		03-10-1996
		EP 0817642 A		14-01-1998
		EP 0815123 A		07-01-1998
		JP 10508034 T		04-08-1998
		JP 10508035 T		04-08-1998
		US 6020331 A		01-02-2000
		WO 9630035 A		03-10-1996
WO 9622304	A 25-07-1996	AU 4761996 A		07-08-1996
		CA 2210349 A		25-07-1996
		EP 0804460 A		05-11-1997
		JP 10512570 T		02-12-1998
WO 9403494	A 17-02-1994	AU 679460 B		03-07-1997
		AU 5000693 A		03-03-1994
		CA 2141447 A		17-02-1994
		EP 0656907 A		14-06-1995
		JP 7509723 T		26-10-1995
		US 5475085 A		12-12-1995
		US 5670155 A		23-09-1997
		US 5672681 A		30-09-1997
WO 9213878	A 20-08-1992	AU 1570292 A		07-09-1992
		AU 680379 B		24-07-1997
		AU 3066495 A		18-01-1996
		CA 2103577 A		08-08-1992
		EP 0573608 A		15-12-1993
		JP 6505486 T		23-06-1994
		US 5440013 A		08-08-1995
		US 5475085 A		12-12-1995
		US 5670155 A		23-09-1997
		US 5618914 A		08-04-1997
		US 5672681 A		30-09-1997
		US 5674976 A		07-10-1997